Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 08, 2022

Safety Profile of T-DM1 in HER2-Positive Advanced Breast Cancer: Final Results of the Global and Asia Cohorts of the KAMILLA Trial



Additional Info

Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer
ESMO Open 2022 Sep 06;7(5)100561, R Wuerstlein, P Ellis, F Montemurro, A Antón Torres, S Delaloge, Q Zhang, X Wang, S Wang, Z Shao, H Li, A Rachman, M Vongsaisuwon, H Liu, S Fear, C Peña-Murillo, C Barrios

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading